Completed PHASE1 NCT00003370

Irofulven in Treating Children With Recurrent or Refractory Solid Tumors

A Trial of MGI 114 in Children With Solid Tumors: A Pediatric Oncology Group Phase I Cooperative Agreement Study

Sponsor: National Cancer Institute (NCI)

Conditions Unspecified Childhood Solid Tumor, Protocol Specific

Interventions irofulven

Updated 7 times since 2017 Last updated: Feb 4, 2013 Started: Aug 31, 1998 Primary completion: Mar 31, 2006

A PHASE1 clinical study on Unspecified Childhood Solid Tumor, Protocol Specific, this trial is completed. The trial is conducted by National Cancer Institute (NCI) and has accumulated 7 data snapshots since 1998. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

Change History

7 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE1
Sep 2024 — Sep 2025 [monthly]

Completed PHASE1
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1
Jan 2021 — Jul 2024 [monthly]

Completed PHASE1
Jun 2018 — Jan 2021 [monthly]

Completed PHASE1

▶ Show 2 earlier versions

Feb 2017 — Jun 2018 [monthly]

Completed PHASE1
Jan 2017 — Feb 2017 [monthly]

Completed PHASE1

First recorded

Aug 1998

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

National Cancer Institute (NCI)

Data source: National Cancer Institute (NCI)

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Ann Arbor, United States , Atlanta, United States , Baltimore, United States , Boston, United States , Buffalo, United States , Charleston, United States , Chicago, United States , Cincinnati, United States , Columbus, United States , Dallas, United States and 37 more locations